articleTop 1% cited

VEGF<sub>164</sub>Is Proinflammatory in the Diabetic Retina

Investigative Ophthalmology & Visual Science · 2003 · Vol. 44(5) · pp. 2155–2155

Susumu Ishida✉(Keio University)Tomohiko Usui(The University of Tokyo)Kenji Yamashiro(Kyoto University)Yuichi Kaji(Massachusetts Eye and Ear Infirmary)Ednan Ahmed(Harvard University)Karen G. Carrasquillo(Harvard University)Shiro Amano(The University of Tokyo)Tetsuo Hida(Kyorin University)Yoshihisa Oguchi(Keio University)Anthony P. Adamis(Harvard University)

View via DOI Publisher page

Abstract

On an equimolar basis, VEGF(164) is at least twice as potent as VEGF(120) at inducing ICAM-1-mediated retinal leukostasis and BRB breakdown in vivo. The inhibition of diabetic retinal leukostasis and BRB breakdown with EYE001 in early and established diabetes indicates that VEGF(164) is an important isoform in the pathogenesis of early diabetic retinopathy.

Retinal Diseases and Treatments Angiogenesis and VEGF in Cancer Retinal and Macular SurgeryLeukostasisRetinalBlood–retinal barrierRetinaVascular endothelial growth factorDiabetic retinopathyInternal medicineEndocrinologyMedicinePharmacology

MeSH terms

AnimalsBlood-Retinal BarrierCapillary PermeabilityConcanavalin ADiabetes Mellitus, ExperimentalDiabetic RetinopathyEnzyme-Linked Immunosorbent AssayImmunohistochemistryInjectionsLymphokinesOligonucleotidesRetinal VesselsVitreous BodyBlotting, WesternEndothelial Growth Factors

Citations

366

FWCI

13.82

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease